What's Happening?
CryoTherapeutics has partnered with SpectraWAVE and the Cardiovascular Research Foundation (CRF) to launch the ICECAP clinical study, targeting non-obstructive high-risk coronary plaques using cryotherapy and advanced imaging. The study will utilize SpectraWAVE's
HyperVue Imaging System, combining DeepOCT and NIRS technologies to assess plaque characteristics and the biological effects of cryotherapy. The collaboration aims to stabilize high-risk plaques, which are major drivers of myocardial infarction, through innovative imaging and treatment approaches.
Why It's Important?
The ICECAP study represents a novel approach to treating coronary artery disease, focusing on plaques that are often undetectable through traditional methods but pose significant risks. By integrating advanced imaging and cryotherapy, the study seeks to improve patient outcomes by preventing plaque rupture and subsequent heart attacks. This collaboration highlights the potential of combining cutting-edge technology with innovative treatment methods to address critical unmet needs in cardiovascular care.
What's Next?
The ICECAP study is set to begin patient recruitment in early 2026 across multiple centers in Belgium and the UK. As the study progresses, CryoTherapeutics and SpectraWAVE plan to share findings at major scientific meetings, potentially influencing future treatment protocols for high-risk coronary plaques. The success of this study could lead to broader adoption of cryotherapy and advanced imaging in cardiovascular treatment, offering new hope for patients with coronary artery disease.
